Immune checkpoints, most notably cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), inhibit effector T lymphocytes to limit the anti-tumor autoimmune response [137]. Here, PDCD1 is linked to neoplasm.